The significance of the study:
Given that: (1) 15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD; and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.
Research findings to Therapeutic opportunity:
This study suggests a probiotic-based therapy for lowering cholesterol and triglyceride levels and to treat Non-alcoholic fatty liver disease (NAFLD).
Bifidobacterium pseudocatenulatum CECT 7765, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, Bifidobacterium pseudocatenulatum CECT 7765, either alone or in combination with other drugs, may be used to treat NAFLD.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Bifidobacterium pseudocatenulatum CECT 7765 decrease the expression of HMGCR and prevent NAFLD?
# Research cooperation
For purchase and payment details, you may reach us at email@example.com
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Bifidobacterium pseudocatenulatum CECT 7765 decreases the levels of HMGCR, triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 8/December/2018, 10.57 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, kindly drop us a line at firstname.lastname@example.org
Courtesy: When you cite, drop us a line at email@example.com